Natus Medical Inc (BABY) Stake Increased by Arizona State Retirement System

Arizona State Retirement System lifted its position in Natus Medical Inc (NASDAQ:BABY) by 204.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,363 shares of the medical equipment provider’s stock after buying an additional 35,157 shares during the period. Arizona State Retirement System owned approximately 0.17% of Natus Medical worth $2,000,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Pinebridge Investments L.P. increased its holdings in shares of Natus Medical by 267.1% in the fourth quarter. Pinebridge Investments L.P. now owns 15,103 shares of the medical equipment provider’s stock worth $577,000 after purchasing an additional 10,989 shares during the last quarter. Advisory Services Network LLC increased its holdings in shares of Natus Medical by 5,890.3% in the fourth quarter. Advisory Services Network LLC now owns 14,856 shares of the medical equipment provider’s stock worth $567,000 after purchasing an additional 14,608 shares during the last quarter. Wells Fargo & Company MN increased its stake in Natus Medical by 45.9% during the fourth quarter. Wells Fargo & Company MN now owns 145,534 shares of the medical equipment provider’s stock worth $5,558,000 after acquiring an additional 45,793 shares during the last quarter. Swiss National Bank increased its stake in Natus Medical by 4.4% during the fourth quarter. Swiss National Bank now owns 56,500 shares of the medical equipment provider’s stock worth $2,158,000 after acquiring an additional 2,400 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Natus Medical during the fourth quarter worth approximately $433,000. Institutional investors own 95.96% of the company’s stock.

BABY has been the topic of several analyst reports. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 6th. Zacks Investment Research lowered Natus Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, January 11th. Benchmark restated a “buy” rating and set a $49.00 target price (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. William Blair lowered Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Roth Capital set a $39.00 price target on Natus Medical and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $44.33.

Shares of NASDAQ BABY traded down $0.70 during mid-day trading on Monday, hitting $32.95. The stock had a trading volume of 428,202 shares, compared to its average volume of 576,944. Natus Medical Inc has a twelve month low of $28.00 and a twelve month high of $43.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.32 and a quick ratio of 2.54. The company has a market cap of $1,115.85, a price-to-earnings ratio of 22.72 and a beta of 0.47.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 EPS for the quarter, missing the consensus estimate of $0.54 by ($0.12). Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The business had revenue of $131.40 million during the quarter, compared to analysts’ expectations of $131.38 million. During the same period in the previous year, the company posted $0.51 earnings per share. Natus Medical’s revenue for the quarter was up 22.0% compared to the same quarter last year. research analysts expect that Natus Medical Inc will post 1.63 earnings per share for the current year.

Natus Medical announced that its board has approved a share buyback plan on Thursday, February 22nd that allows the company to repurchase $30.00 million in shares. This repurchase authorization allows the medical equipment provider to buy shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

In other news, Director Ken Ludlum sold 4,000 shares of the stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $31.68, for a total transaction of $126,720.00. Following the sale, the director now directly owns 93,825 shares of the company’s stock, valued at approximately $2,972,376. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://theenterpriseleader.com/2018/04/02/arizona-state-retirement-system-has-2-million-position-in-natus-medical-inc-baby.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply